Marketing HPV Vaccine Implications for Adolescent Health and Medical Professionalism

被引:76
作者
Rothman, Sheila M. [1 ]
Rothman, David J. [1 ]
机构
[1] Mailman Sch Publ Hlth, New York, NY USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2009年 / 302卷 / 07期
关键词
HUMAN-PAPILLOMAVIRUS VACCINATION; TYPE-16;
D O I
10.1001/jama.2009.1179
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The new vaccine against 4 types of human papillomavirus (HPV), Gardasil, like other immunizations appears to be a cost-effective intervention with the potential to enhance both adolescent health and the quality of their adult lives. However, the messages and the methods by which the vaccine was marketed present important challenges to physician practice and medical professionalism. By making the vaccine's target disease cervical cancer, the sexual transmission of HPV was minimized, the threat of cervical cancer to adolescents was maximized, and the subpopulations most at risk practically ignored. The vaccine manufacturer also provided educational grants to professional medical associations (PMAs) concerned with adolescent and women's health and oncology. The funding encouraged many PMAs to create educational programs and product-specific speakers' bureaus to promote vaccine use. However, much of the material did not address the full complexity of the issues surrounding the vaccine and did not provide balanced recommendations on risks and benefits. As important and appropriate as it is for PMAs to advocate for vaccination as a public good, their recommendations must be consistent with appropriate and cost-effective use. JAMA. 2009; 302(7):781-786 www.jama.com
引用
收藏
页码:781 / 786
页数:6
相关论文
共 51 条
[1]  
Allen A., 2007, VACCINE CONTROVERSIA, V1st
[2]  
*AM COLL HLTH ASS, HPV VACC TOOLK
[3]  
*AM COLL HLTH ASS, VACC PREV DIS ADV CO
[4]  
*AM COLL HLTH ASS, AM COLL HLTH ASS VOI
[5]  
*AM COLL HLTH ASS, ACHA YEAR REV
[6]  
*AM COLL HLTH ASS, FREE WEBC HPV VACC U
[7]  
[Anonymous], 1991, MMWR Recomm Rep, V40, P1
[8]  
[Anonymous], 1982, MMWR MORB MORTAL WKL
[9]  
[Anonymous], 2006, FDA LIC NEW VACC PRE
[10]  
[Anonymous], 2005, NIH PUBLICATION